Cell assays, mouse skeletal-muscle models and respirometry experiments behind the MOTS-c literature, described by model and measured variable. Research use only.
What the compound is
MOTS-c is a 16-residue peptide with the sequence MRWQEMGYIFYPRKLR, molecular formula C101H152N28O22S2, molecular weight 2174.60 g/mol, CAS number 1627580-64-6. It is described in the literature as a mitochondrial-derived peptide, meaning its coding sequence lies in mitochondrial rather than nuclear DNA, which is the feature that made it interesting to the groups that first characterised it (PMID 25738459). All compounds discussed are supplied strictly as laboratory research materials. They are not for human or veterinary use, and nothing here is medical advice.
Two methionine residues and a tryptophan make this sequence more oxidation-sensitive than a typical short peptide, so analytical work on supplied material has to distinguish the intact peptide from oxidised species. The relevant methods are described in mass spectrometry peptide testing and HPLC peptide purity.
The research question
The MOTS-c literature asks where the peptide sits in cellular energy signalling and what changes when its level changes. Three experimental layers carry that question. In cell culture, the layer is signalling: which kinases are activated in treated cells and which protein the peptide binds directly. In mouse models, the layer is tissue and whole-animal physiology: skeletal muscle composition, glucose handling and measured activity. In isolated mitochondria and permeabilised muscle fibres, the layer is bioenergetics measured by respirometry.
The endpoints throughout are laboratory endpoints: phosphorylation state on immunoblots, binding measured by direct interaction assays, transcript and protein abundance in muscle tissue, oxygen consumption rate in a respirometer, and glucose or insulin measurements in mice. No human outcome is described in this article and none should be read into it.
Cell and signalling models
The founding study combined cell experiments with mouse experiments and placed the peptide in the AMP-activated protein kinase pathway, with metabolic readouts measured in the treated animals and pathway readouts measured in cells (PMID 25738459). The pathway assignment rests on standard signalling measurements: phosphorylation of AMPK and downstream targets on immunoblots from treated cells and tissue.
A more recent study asked a sharper question, which protein the peptide actually touches, and reported direct binding to and activation of casein kinase 2 with skeletal muscle function as the accompanying measurement (PMID 39559755). Direct binding work is a different class of evidence from pathway inference: it uses interaction assays with purified components rather than reading a phosphorylation change downstream and reasoning backwards. When a field moves from the second kind of evidence to the first, the mechanistic claim gets narrower and better supported at the same time.
A structural point about this field deserves emphasis. Because the peptide is encoded in mitochondrial DNA and produced endogenously, an experiment can manipulate it in two opposite ways: by adding synthetic peptide to a cell or animal, or by changing the endogenous level and measuring what follows. The two designs answer different questions, and the resulting literature contains both. A signalling result obtained by adding peptide to cultured cells describes what the cells do under that exposure, and it is not evidence about the role of the endogenous peptide in an untreated animal.
Mouse skeletal muscle and exercise models
Several studies use skeletal muscle in mice as the test tissue. One reported the peptide as an exercise-induced, mitochondrially encoded regulator, measuring age-dependent physical decline and muscle homeostasis in mouse cohorts followed over time (PMID 33473109). Longitudinal designs of that type measure activity, muscle mass and tissue markers at intervals rather than at a single endpoint, which is what allows an age-dependent trajectory to be described at all in the animal model.
Another mouse study combined administration with an exercise intervention and measured PGC-1 alpha expression, insulin sensitivity and glucose handling through AMPK signalling in the treated animals (PMID 33722744). A third measured muscle peptide levels after long-term physical activity in the animal model, together with an acute exercise performance measurement after a single administration (PMID 35808870). These are animal physiology experiments with tissue-level and treadmill-based endpoints; none of them is a statement about people.
Exercise models add their own variability. Treadmill and wheel protocols differ between laboratories in duration, intensity and how animals are habituated, and each of those choices shifts the muscle phenotype being measured. Two mouse studies reporting the same direction of change may therefore have measured quite different interventions. That is not a criticism of any individual report, but it is the reason effect sizes in this corpus should not be compared across studies, and the reason the dependency experiments described below carry more weight than the descriptive ones.
Mitochondrial bioenergetics and secretion
The most direct mitochondrial measurements come from respirometry. One study measured intrinsic muscle mitochondrial bioenergetic health and efficiency and reported the effect as dependent on PGC-1 alpha and AMPK, using genetic or pharmacological removal of those components to test the dependency (PMID 41520850). Dependency experiments of this kind are the strongest design available in this literature: if the measured respiratory change disappears when a named pathway component is removed, the pathway assignment is tested rather than assumed.
The reverse direction has also been examined. In an endurance training model, skeletal muscle mitochondrial respiration was measured alongside secretion of the peptide, treating it as an output of training rather than only an input to metabolism (PMID 39706498). That framing matters for experimental design, because a peptide that is both secreted in response to activity and active on the same tissue creates a loop, and a study that measures only one arm of the loop cannot resolve its direction.
Sequence chemistry also intrudes on the biology in this case. The two methionine residues make the peptide oxidation-sensitive, so material handled or stored poorly can present a mixture of intact and oxidised species in a cell or animal experiment without that being visible in the result. Studies in this field rarely report a purity or oxidation check on the peptide as administered, which leaves a gap between what was intended to be tested and what was measured. For a laboratory repeating any of the work above, closing that gap is an analytical task performed before the biological experiment begins.
Limits of the evidence
This corpus is young, and much of it comes from a small number of laboratories working closely together on the same models. Mouse cohorts are small, exercise protocols differ between studies in ways that make cross-study comparison difficult, and the respirometry work uses preparations, isolated mitochondria and permeabilised fibres, whose behaviour is not identical to intact tissue.
The peptide is also an endogenous molecule, which means administration experiments and endogenous-level experiments are answering different questions and should not be pooled. Everything summarised here was measured in cells, isolated mitochondria or mice. None of it extrapolates to people, and no human outcome is described in this article.
Respirometry preparations warrant a note as well. Isolated mitochondria and permeabilised muscle fibres are chosen because they allow substrates and inhibitors to be controlled directly, but both preparations remove the cell architecture that governs mitochondrial behaviour in intact tissue. An efficiency measurement in a permeabilised fibre is a statement about that preparation under those substrate conditions. It is the most precise measurement in this literature and also the furthest from intact physiology, and both of those facts should be carried when the result is cited.
Related materials in the catalogue
The product page is MOTS-c and the compound guide is the MOTS-c research guide, listed in the cellular category. Related mechanism reading includes the growth-hormone-axis article and the BPC-157 tissue-repair article.
Lot documentation is published under certificates, solvent volumes are calculated with the reconstitution calculator, and the paperwork itself is explained in how to verify a peptide certificate of analysis and what a 99 percent purity figure means. All compounds discussed are supplied strictly as laboratory research materials. They are not for human or veterinary use, and nothing here is medical advice.
References
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell metabolism, 2015. PMID 25738459
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850
- Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion. Free radical biology & medicine, 2025. PMID 39706498
- MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience, 2024. PMID 39559755
- MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiological reports, 2022. PMID 35808870
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature communications, 2021. PMID 33473109
- MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway. Biochimica et biophysica acta. Molecular basis of disease, 2021. PMID 33722744
Research use only